Publication

Bisoprolol Pilot Studies in Myocardial Infarction

De Muinck, E. D., Lie, K. I., Von Mengden, H. J., Reck, R. & Verkenne, P., 1990, In : Journal of Cardiovascular Pharmacology. 16, p. S196-S200 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Bisoprolol pilot studies in myocardial infarction

    Final publisher's version, 391 KB, PDF document

    Request copy

  • E. D. De Muinck
  • K. I. Lie
  • H. J. Von Mengden
  • R. Reck
  • P. Verkenne

The efficacy of beta-blockade after myocardial infarction (MI) has been investigated in a series of studies. When beta-blockers are used during the first hours after the onset of MI, a reduction in infarct size, mortality, and nonfatal reinfarction may occur. Bisoprolol is a highly beta-1-selective beta-blocker, without intrinsic sympathomimetic activity (ISA), and with a plasma elimination half-life of 10-12 h, permitting treatment with one daily dose. Because no experience with bisoprolol was available in MI, its safety and efficacy were studied in two open, uncontrolled pilot studies. The first study was a dose-finding study in 37 patients with a 3-day-old MI. Bisoprolol was given intravenously and carefully titrated in steps of 1 mg up to a cumulative maximum dose of 5 mg. Subsequently, the patients received 10 mg of oral bisoprolol once daily (o.d.) until the end of the study. Based on the results of this first pilot study, a second pilot study was performed in which bisoprolol was given within the first 6 h after the onset of MI. Intravenous (i.v.) bisoprolol was titrated in two steps of 2.5 mg each, directly followed by 10 mg of oral bisoprolol o.d. The aim of this study was to investigate the influence of i.v. and subsequent oral bisoprolol on central hemodynamics. The results of these studies demonstrate that i.v. and subsequent oral administration of bisoprolol is well tolerated and indicate that the selected dose regimen is hemodynamically safe.

Original languageEnglish
Pages (from-to)S196-S200
Number of pages5
JournalJournal of Cardiovascular Pharmacology
Volume16
Publication statusPublished - 1990
Event3RD INTERNATIONAL SYMP ON BISOPROLOL : THE ROLE OF BETA-BLOCKADE IN MODERN CARDIOVASCULAR THERAPY - , Spain
Duration: 29-Sep-19891-Oct-1989

Event

3RD INTERNATIONAL SYMP ON BISOPROLOL : THE ROLE OF BETA-BLOCKADE IN MODERN CARDIOVASCULAR THERAPY

29/09/198901/10/1989

Spain

Event: Other

    Keywords

  • BISOPROLOL, BETA-BLOCKADE, INFARCT SIZE, HEART RATE REDUCTION, CENTRAL HEMODYNAMICS, ADRENOCEPTOR ANTAGONIST, METOPROLOL, BLOCKADE

ID: 6278248